TrialOphthalmology2024

Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.

Henry E Wiley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.